PointState Capital’s Karyopharm Therapeutics KPTI Stock Holding History

PointState Capital’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-10,000	Closed	-$4.59M	–	166
2015 Q1	$4.59M	Buy	10,000 +3,333	+50%	+$1.44M	0.06%	98
2014 Q4	$3.74M	Hold	6,667	–	–	0.06%	94
2014 Q3	$3.49M	Sell	6,667 -3,333	-33%	-$1.88M	0.06%	82
2014 Q2	$6.98M	Buy	10,000 +6,667	+200%	+$3.1M	0.09%	89
2014 Q1	$1.54M	Buy	+3,333	New	+$1.69M	0.02%	109

Other funds holding KPTI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

PointState Capital's KPTI Position: Q2 2015 in Review

PointState Capital sold out of Karyopharm Therapeutics (KPTI) in Q2 2015, closing a stake of 10,000 shares — an estimated $4.59M sold.

PointState Capital first reported a position in KPTI in Q1 2014 and held it in 5 quarters. The position peaked at $6.98M in Q2 2014. 89 funds tracked by Wall St. Rank hold KPTI as of Q2 2015.

PointState Capital reported no remaining Karyopharm Therapeutics position as of Q2 2015 after selling out during the quarter.
PointState Capital sold 10,000 Karyopharm Therapeutics shares in Q2 2015, an estimated $4.59M.
PointState Capital first reported a position in Karyopharm Therapeutics in Q1 2014 and held it in 5 quarters.
PointState Capital's Karyopharm Therapeutics position peaked at $6.98M in Q2 2014.
89 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2015.

Based on PointState Capital's 13F filing for Q2 2015, filed 14 Aug 2015.